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Abstract
Background: The highest rates of cervical cancer are found in developing countries. Frontline
monitoring has reduced these rates in developed countries and present day screening programs
primarily identify precancerous lesions termed cervical intraepithelial neoplasias (CIN). CIN lesions
described as mild dysplasia (CIN I) are likely to spontaneously regress while CIN III lesions (severe
dysplasia) are likely to progress if untreated. Thoughtful consideration of gene expression changes
paralleling the progressive pre invasive neoplastic development will yield insight into the key casual
events involved in cervical cancer development.
Results: In this study, we have identified gene expression changes across 16 cervical cases (CIN I,
CIN II, CIN III and normal cervical epithelium) using the unbiased long serial analysis of gene
expression (L-SAGE) method. The 16 L-SAGE libraries were sequenced to the level of 2,481,387
tags, creating the largest SAGE data collection for cervical tissue worldwide. We have identified
222 genes differentially expressed between normal cervical tissue and CIN III. Many of these genes
influence biological functions characteristic of cancer, such as cell death, cell growth/proliferation
and cellular movement. Evaluation of these genes through network interactions identified multiple
candidates that influence regulation of cellular transcription through chromatin remodelling
(SMARCC1, NCOR1, MRFAP1 and MORF4L2). Further, these expression events are focused at the
critical junction in disease development of moderate dysplasia (CIN II) indicating a role for
chromatin remodelling as part of cervical cancer development.
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Conclusion: We have created a valuable publically available resource for the study of gene
expression in precancerous cervical lesions. Our results indicate deregulation of the chromatin
remodelling complex components and its influencing factors occur in the development of CIN
lesions. The increase in SWI/SNF stabilizing molecule SMARCC1 and other novel genes has not been
previously illustrated as events in the early stages of dysplasia development and thus not only
provides novel candidate markers for screening but a biological function for targeting treatment.
Background
Cervical cancer affects approximately 500,000 women
worldwide each year with highest rates in developing
countries [1]. Cervical intraepithelial neoplasia (CIN) is a
precursor lesion to cervical cancer and can be further sub-
divided into CIN I, CIN II and CIN III (mild, moderate
and severe dysplasia, respectively). Most CIN I lesions
spontaneously regress to normal however CIN III lesions
are much more likely to progress to cervical cancer if left
untreated [1]. The CIN I to CIN II junction may be critical
in disease development.
Human Papillomavirus (HPV) is the recognized etiologic
agent for cervical cancer however, alone it is not sufficient
for invasive disease. HPV is detected in nearly all cervical
cancers, 94% of CIN lesions and up to 46% of normal cer-
vical epithelium [1]. Over 100 strains of HPV exist how-
ever HPV 16 and HPV 18 are considered highly virulent
strains and account for the majority of cervical cancers
[1,2].
The study of cervical cancer prevention has progressed
impressively in the recent past. Widely implemented
screening programs have resulted in 80% reduction of cer-
vical cancer rates in North America within the past fifty
years [3]. Cytological assessment is currently the frontline
method for identifying precancerous cervical lesions how-
ever repeat evaluations can frequently be required due to
low sensitivity [3]. Although vaccines against the most vir-
ulent strains of HPV have recently become available, vac-
cination is not an easily utilized resource for those
countries most inflicted with the highest cervical cancer
rates [3]. This is largely due to cost and that the adminis-
tration of the vaccine occurs in three doses over six
months to a pre-adolescent female population. Few coun-
tries have established programmes targeting healthcare to
this population [4]. In addition, perceived social implica-
tions in developed countries regarding vaccinating girls at
an early age are hindering widespread administration.
Together, these social, clinical and genetic factors indicate
that frontline monitoring will continue to play an impor-
tant role in cervical cancer prevention and that improved
methods and markers for detection are needed.
It is unclear that HPV alone is responsible for disease pro-
gression. A thorough understanding of genetic events in
precancerous cervical intraepithelial neoplasia is required
to both delineate important causal events in cervical can-
cer and to identify informative candidate biological mark-
ers. Gene expression of cervical tissue and changes in
expression pattern have been the focus of several recent
publications. Studies by Pérez-Plasencia et al and Shadeo
et al both characterized the transcriptome of normal cer-
vical epithelium using serial analysis of gene expression
(SAGE) [5,6], Additionally, Gius et al reported changes in
proproliferative/immunosuppression gene expression in
CIN I lesions, as well as proangiogenic and proinvasive
expression signatures that coincide with CIN II and CIN
III, respectively [7].
In this study, we build upon our previous work in defin-
ing the normal cervical epithelial transcriptome and aim
to identify genes differentially expressed between normal
cervical epithelium and those precancerous lesions which
are more apt to progress to cervical cancer if left without
treatment (CIN III). In this study we have distinguished
gene expression aberrations across mild/moderate dyspla-
sia (CIN I, CIN II) in addition to CIN III and non cancer-
ous (NC) cervical epithelium using an unbiased long
serial analysis of gene expression (L-SAGE) method that
simultaneously allows for the discovery of tags which map
to HPV 16. In total, sixteen L-SAGE libraries were
sequenced for a total of 2,481,387 tags, establishing the
largest SAGE data collection for cervical tissue worldwide.
Upon evaluation of expression differences between NC
cervical epithelium and CIN lesions, we have identified
two gene networks directly or indirectly involved in chro-
matin remodelling altered in expression in CIN III.
Results
L-SAGE Libraries from Cervical Tissue
In this study 16 L-SAGE libraries were constructed and
analyzed (Figure 1). Libraries N1 to N4 were made from
NC cervical tissue samples, M1 to M3 from CIN I samples,
M4, to M6 from CIN II samples and C1, to C6 from CIN
III samples. N1, N2, C1 and C2 were mined in a prelimi-
nary study characterizing normal cervical tissue [6]. Col-
lectively, 2,481,387 useful tags were sequenced (Figure 1).
This data collection has been made publicly available at
Gene Expression Omnibus, series accession number
GSE7433 [8].BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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Early Stage Changes
The mean tag counts were compared between NC tissue
samples (libraries N1-4) and mild/moderate stage (CIN I/
II) samples (libraries M1-6) in order to identify tags differ-
entially expressed in the early stages of neoplasia. One-
hundred sixty-nine tags were identified to be differentially
expressed according to our selection criteria as described
in Methods [see Additional file 1]. Both increased and
decreased expression is observed at comparable frequen-
cies (75 tags increased, 94 tags decreased in CIN I/II) and
138 of these tags mapped to known genes including loci
encoding hypothetical proteins.
The most commonly affected biological process in the
early events of disease is DNA dependent regulation of
transcription and transcription (11% and 8% of differen-
tially expressed tags, as assessed by Onto-Express, respec-
tively) (Figure 2A) [9,10].
Late Stage Changes
The mean tag counts were compared between CINI/II tis-
sue samples (libraries M1-6) and CIN III libraries (C1-6).
This identified 128 tags differentially expressed in later
stages of neoplasia [see Additional file 2]. Seventy-three
tags were increased in CIN III while 55 were decreased.
Overall 97 tags mapped to known genes. The major path-
ways affected by these genes were similar to those
observed in early stage changes, DNA dependent regula-
tion of transcription and transcription (8% and 7% as
assessed by Onto-Express. respectively) (Figure 2B) [9,10].
Twelve tags mapped to the HPV 16 genome that could not
be mapped to the human genome or transcripts using
methods previously described [see Additional file 3]. [6].
In addition, 42 tags showed concurrent expression
between all sixteen libraries [see Additional file 4].
Pathway Analysis of Overall Changes
The mean score of tags in the four NC libraries were com-
pared to the mean score of tags in the six severe neoplasia
libraries (CIN III). We identified 108 tags increased in fre-
quency in CIN III and 138 tags decreased and overall
observed 246 tags differentially expressed between NC tis-
sue and CIN III [see Additional file 5]. Two hundred and
forty tags mapped to 222 unique genes. Genes differen-
tially expressed between normal and CIN III were evalu-
ated for gene network associations using Ingenuity
Pathway Analysis [11]. Biological functions most influ-
enced by these genes include cell death, cell growth/pro-
liferation and cellular movement (Figure 3). The gene
network with the most number of differentially expressed
genes influenced cellular processes such as cell cycle and
cell morphology and involved 17 of the differentially
expressed genes (Table 1, Figure 4). The network with the
higher magnitude gene expression changes influenced cell
cycle and gene expression (Figure 5).
Eight genes from these networks were selected for valida-
tion in an independent panel of cervical samples (Table
2). Cyclin-dependent kinase inhibitor 2B (CDKN2B),
retinoblastoma-like 2(p130 or RBL2) and phosphatase
and tensin homolog (PTEN) had lower counts in the CIN
III derived libraries. Conversely, Mof4 family associated
protein 1 (MRFAP1), mortality factor 4 like 2(MORF4L2),
nuclear receptor co-repressor 1 (NCOR1), dihydrofolate
reductase (DHFR) and SWI/SNF related, matrix associ-
ated, actin dependent regulator of chromatin, subfamily c,
member 1(SMARCC1) showed higher tag counts in the
CIN III relative to NC.
The validation panel consists of 22 samples representing
NC, CIN I, CIN II and CIN III in addition to a tumor sam-
ple with paired normal tissue. Quantitative analysis of
expression was determined for each gene on this panel by
real-time PCR using TaqMan®  Gene Expression Assays
(Figure 6). NCOR1 expression increased in nine of ten
CIN I/II samples ranging from 1.3–6.0 fold increase rela-
tive to NC with a statistically significant overall all trend
(p < 0.05). SMARCC1 expression increase was confirmed
in six CIN I/II samples and four CIN III cases (Figure 6).
Similarly, we confirmed the increased expression of DHFR
and MRFAP1 in the validation panel including in nine of
Summary of L-SAGE library analysis Figure 1
Summary of L-SAGE library analysis. Sixteen L-SAGE 
libraries were created and a total of 2,481,387 useful tags 
were sequenced. An average of 130,560 tags were sequenced 
per NC library (4), 155,807 per CIN I/CIN II library (6) and 
170,718 per CIN III library (6). One-hundred and sixty-nine 
tags were differentially expressed when comparing NC to 
CIN I/CIN II, 246 between NC and CIN III and 128 tags were 
differentially expressed between CIN I/CIN II and CIN III. 
Eight candidates were identified for greatest amplitude of 
change between NC and CIN III and gene network most 
affected.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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ten CIN I/II cases and six of seven CIN III cases and the
overall trend of increase for this gene was statistically sig-
nificant (p < .05). MORF4L2 expression increase was con-
firmed in eight of ten CIN I/II and six of seven CIN III with
statistically significant overall trend of increase (p < .05) in
the validation panel. Although we were able to confirm
decreased CDKN2B expression in the tumour, we were
unable to confirm this in the earlier staged cases in the val-
idation panel. Reduced expression of phosphatase and
tensin homolog (PTEN) was confirmed in two CIN II and
two CIN III cases [see Additional file 6].
Functional groupings of tags differentially expressed in SAGE libraries Figure 2
Functional groupings of tags differentially expressed in SAGE libraries. (A) Genes differentially expressed between 
NC and CIN I/CINII. (B) Genes differentially expressed between CIN I/CIN II and CIN III. Categories are as described. The 
Unknown function group consists of tags mapping to genes with no known function. DNA Dependent Regulation of Transcrip-
tion was the function most targeted in both groups of differentially expressed tags.
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Discussion
The study of precancer lesions is essential in understand-
ing the initiating events in cancer development and is of
particular importance in cervical cancer as moderate and
high grade lesions (CIN II and CINIII) are more likely to
progress to cancer than those of low grade (CIN I). In this
study, we have comprehensively evaluated gene expres-
sion changes in the precancerous stages of cervical cancer
by comparing 16 cervical intraepithelial neoplasia and
NC cervical specimens using the L-SAGE method of gene
expression profile determination. We have sequenced a
total of 2,481,387 tags, establishing the largest SAGE data
collection for cervical tissue worldwide. CIN I, CIN II,
CINIII as well as normal tissues are represented in this col-
lection. In a preliminary study, we had identified Keratin
6A (KRT6A), carcinoembryonic antigen-related cell adhe-
sion molecule 7 (CEACAM7), S100 calcium-binding pro-
tein A7 (S100A7) and small proline-rich protein 3
(SPRR33) to be highly expressed (>500 TPM) in NC cervi-
cal tissue in the N1 and N2 libraries [6]. Tags mapping to
Biological functions targeted by gene expression changes between NC and CIN III Functional categories deemed as significant  by Ingenuity Pathway Analysis software, are displayed along the x-axis Figure 3
Biological functions targeted by gene expression changes between NC and CIN III Functional categories 
deemed as significant by Ingenuity Pathway Analysis software, are displayed along the x-axis. The y-axis displays 
the -(log) significance and the orange horizontal line denotes the cut off for significance (p-value of 0.05). The functional catego-
ries most significantly influenced include cell death, cell growth and proliferation and cell movement.
Table 1: Genes differentially expressed in Networks A and B.
Network IPA Score* Increased in CIN III Decreased in CIN III
A 22 BH3 interacting domain death agonist cyclin-dependent kinase inhibitor 2B
cytochrome b-561 Cbp/p300-interacting transactivator, with
dihydrofolate reductase Glu/Asp-rich carboxy-terminal domain, 2
nuclear receptor co-repressor 1 endothelin 3
sialidase 1 interferon-related developmental regulator 1
peptidyl-prolyl cis/trans isomerase, NIMA- Kruppel-like factor 6
interacting phosphatase and tensin homolog RAB4A
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1
retinoblastoma-like 2 (p130)
B 17 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 
5
adaptor-related protein complex 3, mu 2 subunit
B double prime 1, subunit of RNA polymerase III transcription 
initiation factor IIIB
cyclin-dependent kinase inhibitor 2B cellular 
repressor of E1A-stimulated genes 1
creatine kinase, brain Kruppel-like factor 6
mortality factor 4 like 2 keratin 17
Mof4 family associated protein 1 tropomodulin 3
ribophorin I
stomatin (EPB72)-like 2
* The score is a numerical value used to rank networks according to how relevant they are to the genes in your input dataset. Calculations are 
based on the hypergeometric distribution calculated via the computationally efficient Fisher's Exact Test for 2 × 2 contingency tables8. Gene 
symbols in bold denote those selected for validation in a new panel of fourteen cases.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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these genes are present at high levels in the additional nor-
mal libraries (N3 and N4) unique to this study with the
exception of CECEAM7 which shows slightly reduced
expression of 363 and 397 TPM (N3 and N4, respec-
tively). The decreasing trend in Galectin 7 (LGALS7) and
Gap junction protein A1 (GJA1) previously observed in
CIN III when compared to normal mean values, continues
to be true in this study (3.0 and 1.7 fold decrease in CIN
III, respectively, p value not significant).
Gene Network A Figure 4
Gene Network A. Green denotes loss in expression in CIN III while red indicates gain. Intensity of colour signifies magnitude 
of change. Solid lines indicated direct interactions while dashed lines indicate indirect interactions as described by Ingenuity 
Pathway Systems. Functions influenced by Network A include cell cycle, cancer and cell morphology.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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Early and Late Events
Of the tags differentially expressed between NC and mild/
moderate dysplasia (169 tags), and between mild/moder-
ate and severe dysplasia (128 tags); 25% fewer tags were
altered in later stage disease. These differentially expressed
tags most frequently mapped to genes involved in DNA
dependent regulation of transcription. Interestingly, tags
mapping to genes with biological functions unique to late
stage changes include cell cycle (5% of tags), cell division
(3%), immune (4%) and inflammatory (3%) response.
Gene Network B Figure 5
Gene Network B. Green denotes loss in expression in CIN III while red indicates gain. Intensity of colour signifies magnitude 
of change. Solid lines indicated direct interactions while dashed lines indicate indirect interactions as described by Ingenuity 
Pathway Systems. Functions influenced by Network B include cell cycle, gene expression and cancer specific function.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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Biological Characteristics of Differentially Expressed Tags
Of the 246 tags that are altered in expression in CIN III rel-
ative to NC, cell death, cell growth and proliferation, cell
movement, cell cycle and DNA replication, recombina-
tion and repair are the top five biological functions. These
functions encompass characteristics frequently described
as the hallmarks of cancer [12].
Tags mapping to seven unique genes showed a greater
than ten fold increase in expression in CIN III libraries. A
tag mapping to SEC13 homolog (SEC13L1) showed the
greatest change as it was not present in any one of the four
NC libraries. However, an average of 20 TPM were
observed in CIN III libraries. Additional tags with greater
than ten fold change mapped to MORF4L2, MRFAP1, WD
repeat domain 18(WDR18), SMARCC1, eukaryotic trans-
lation elongation factor 1 gamma (EEF1G) and G protein-
coupled receptor 180 (GPR180). SMARCC1 is a compo-
nent of the chromatin remodeling complex SWI/SNF
while both MRFAP1 and MORF4L2 belong to the MGF/
MORF family of transcription factors involved in growth,
cell senescence and are implicated indirectly in chromatin
remodeling [13-18]. WDR18  is a member of the WD
repeat protein family. Members of this gene family are
involved in a variety of cellular processes including cell
cycle progression, signal transduction, apoptosis, and
gene regulation [19]. Tags mapping to this gene varied in
counts between NC and CIN III by greater than twelve
fold increase in the latter subgroup. EEF1G is a subunit of
the elongation factor-1 complex involved in translation
and GPR180 contains transmembrane domains and may
play a role in vascular remodelling [20]. It is interesting to
note that both homeobox B7 (HOXB7) and BH3 interact-
ing domain death agonist (BID) are also increased in CIN
III although to a lesser magnitude (seven and five fold,
respectively). Many of the described genes may have the
potential to influence processes characteristic of epithelial
cancers such as, apoptosis (BID), angiogenesis (GPR180),
proliferation (WDR18), and transcription influencing
events (SMARCC1, MRFAP1, MORFL2). Functional assays
are required to delineate their biological function in CIN
and cervical cancer.
Network Analysis
Upon further investigation of the 246 differentially
expressed tags between NC and CIN III, 240 mapped to
222 unique genes. When analyzed for gene network rela-
tionships, many of the genes targeted pathways influenc-
ing properties such as cell cycle, cell morphology, cancer
related events and gene expression. In this study, we have
identified a group of 28 genes that fall into two gene net-
works encompassing these properties. The first network
(A) contains 15 of the differentially expressed genes while
the second network (B) includes 13 of the 222 genes.
Only cyclin-dependent kinase inhibitor 2b (CDKN2B)
and kruppel-like factor 6 (KLF6) overlap between Net-
work A and B. Network B includes three of the seven tags
showing greater than 11 fold change and one of the five
tags showing more than 20 fold decrease in NC when
compared to CIN III. Genes from both networks were
selected for validation in a new cervical tissue panel.
Network A
Cell cycle, cancer and cell morphology are the top func-
tions influenced by genes in Network A. Sixteen genes dif-
ferentially expressed between NC and CIN III are involved
in this network including RBL2/p130, SMARCC1, NCOR1,
PTEN, DHFR and CDKN2B.
RBL2/p130 is one of three members of the Retinoblastoma
(Rb) gene family, others include RBL1/p107 and RB1 [21].
This family of proteins regulate cell cycle through the G1/
S phase by sequestering E2F transcriptional regulators.
Loss and mutations in RBL2/p130 have been linked to var-
ious cancers [22,23]. E7 from high risk HPV strains targets
all member of the Rb family including RBL2/p130, for
degradation thus releasing sequestered E2F and allowing
for passage through the G1/S phase [24,25]. Zhang et al
found that low risk HPV 6 E7 also has the capacity to bind
RBL2/p130 although not with as high affinity and did not
bind to the other member of the Rb family [25]. We
observed a progressive reduction in RBL2/p130 transcripts
from NC to mild/moderate dysplasia and severe dysplasia
suggesting that a reduction in RBL2/p130 may also be reg-
ulated at the transcriptional level in cervical preneoplasia
Table 2: Candidate genes in Networks A and B.
Gene P Score N vs CINIII NC Mean CINI/II Mean CINIII Mean Fold Change
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1
2.78 1.83 7.49 20.21 11.02
Mof4 family associated protein 1 2.14 1.83 3.64 23.67 12.90
mortality factor 4 like 2 3.36 1.78 18.65 35.20 19.78
nuclear receptor co-repressor 1 2.36 12.65 38.27 42.02 3.32
dihydrofolate reductase 2.68 10.07 28.04 27.47 2.73
cyclin-dependent kinase inhibitor 2B 2.56 23.95 9.32 3.67 -6.53
retinoblastoma-like 2 (p130) 2.43 31.05 15.54 5.70 -5.45
phosphatase and tensin homolog 2.32 20.42 4.95 5.89 -3.47BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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and may be the first Rb family gene event in the develop-
ment of cervical intraepithelial neoplasia.
SMARCC1 is a member of the SWI/SNF family of genes.
Members of this evolutionarily conserved gene family are
proposed to regulate gene specific transcription with
downstream effects in cell cycle progression [26].
SMARCC1 has recently been reported to directly interact
with components of the ATP-dependent SWI/SNF chro-
matin remodelling complex including, SWI/SNF-related,
matrix-associated, actin-dependent regulator of chroma-
tin A4 (BRG1), BRG1-associated factor A (BAF60a) and
SWI/SNF-related, matrix-associated, actin-dependent reg-
ulator of chromatin B1 (SNF5) [15]. The SWI/SNF chro-
matin remodelling complex consists of approximately ten
components and is thought to regulate gene transcription
by altering the surrounding chromatin structure. This
complex can recruit both histone acetyltransferases
Summary of validation panel quantitative PCR results of genes with altered expression in CIN III L-SAGE libraries Figure 6
Summary of validation panel quantitative PCR results of genes with altered expression in CIN III L-SAGE 
libraries. A panel of 22 new cases was investigated in triplicate for expression changes for eight genes. Samples are indicated 
as follows: CIN I (A-C), CIN I/II (D), CIN II (E-J), CIN III (K-Q) and tumour (R). Zero on the Y-axis denotes mean expression 
levels of the respective genes in three NC cervical tissues. Expression in tumour is relative to matched normal.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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(HATs) and histone deacetyltransferases (HDACs) in a
gene specific manner thus influencing gene expression
[27]. The SWI/SNF chromatin remodelling complex also
has been implicated in hormone receptor signalling and
growth [16]. SMARCC1 was characterized as a key regula-
tor of core complex components (BRG1, BAF60a and
SNF5) by positively influencing the stabilization of the
complex proteins as opposed to regulation of their tran-
scription [15]. In our study, there was no expression
change in these core components. In contrast, we
observed an 11 fold increase in tags mapping to
SMARCC1 in CIN III libraries when compared to normal
libraries suggesting that SWI/SNF chromatin remodelling
complex stability may have a role in severe dysplasia
development.
DHFR is involved in folate metabolism in eukaryotes and
is essential for purine and thymidylate biosynthesis and
thus DNA replication [28]. We observed over a 250%
increase in both mild/moderate and severe dysplasia as
compared to normal, indicating that this event is present
in very early stage lesions. It has recently been reported
that DHFR  is subjected to RB mediated repression via
SWI/SNF chromatin remodelling activity [29]. The
increase in DHFR observed is in concordance with the
expected downstream effects of decreased RB gene family
repression.
NCOR1 is involved in transcription repression via chro-
matin condensation. It has been found to physically inter-
act with members of the SWI/SNF complex, including
SMARCC1 and core component BRG1 [30]. We observed
greater than 300% increase in NCOR1 in severe and mild/
moderate dysplasia relative to normal suggesting an
increase in NCOR1 occurs very early in disease develop-
ment (CIN II/CIN I).
Phosphatase and tensin homolog (PTEN), an established
tumour suppressor gene, functions through the AKT/PKB
signalling pathway [31]. We found PTEN to decrease in
expression in CIN II/CIN I libraries by >3 fold compared
to normal indicating that this may be an early event.
CDKN2B negatively regulates CDK4 and CDK6 [32]. We
found CDKN2B decreased in CIN III libraries by nearly
3.5 fold when compared to NC. Decreased expression of
CDKN2B has not been found due to copy number loss or
mutation in cervical cancer [32].
Genes from Network A were selected for validation in a
new 14 sample set consisting NC, CIN I, CIN II and CIN
III cervix tissue and one tumour and normal pair. A simi-
lar pattern of fold change is present in this panel for
DHFR,  SMARCC1  and  NCOR1  in all three subgroups.
Specifically, increased expression is observed in all three
CIN II and two CIN III in the new cervical tissue panel,
validating the disruption of genes involved in chromatin
remodelling.
For PTEN, we observed a decrease in one of the three CIN
III cases investigated which is consistent with Lee et al
who found PTEN to be reduced in protein expression in
only 10% of CIN III cervical cases and 18% of cervical can-
cers [33]. We also found CDKN2B to be over expressed in
all CIN I, two CIN II and one CIN III however, greater
than four fold decrease in cervical cancer (T1) was
observed. It has been reported that cervical cancers and
CIN III lesion have elevated levels of CDKN2B (84% and
79%, respectively) [34].
Network B
Fourteen genes differentially expressed between normal
and CIN III targeted Network B including MRFAP1,
MORFL2 and CDKN2B. Top functions influenced by Net-
work B include cancer related factors, cell cycle and gene
expression. The previously discussed gene CDKN2B over-
laps with this network.
MRFAP1 binds with strong affinity to mortality factor 4
like 1 (MRG15) [17]. MRG15 is a member of the MRG/
MORF family of genes. All members contain a MRG
domain which has the capacity to bind multiple transcrip-
tional regulators [18]. Members of this gene family are
suggested to be involved in embryonic development, cell
proliferation and senescence [35]. MRG15 is a compo-
nent of the MRG associated factors 1 and 2 complexes
(MAF1, MAF2, respectively) and thus has a putative role
in chromatin remodelling [36]. MRG15 has been shown
to specifically associate with MRFAP1 in MAF1, tumour
suppressor RB and the mammalian co repressor complex,
mSin3A [14,35]. We observed a 12.9 fold increase of
MRFAP1 in CIN III libraries when compared to NC librar-
ies. Notably, the majority of this increase occurs between
mild/moderate and severe dysplasia. Although the biolog-
ical mechanisms of MRFAP1 and MRG15 interaction has
yet to be described, it is plausible that the relationship
may influence the essential role MRG15 plays in chroma-
tin remodelling.
We observed a 20 fold increase of MORF4L2 in CIN III
libraries. Like MRG15,  MORF4L2  also belongs to the
MRG/MORF transcriptional regulator family of genes
involved in senescence and cell growth [37]. Although the
two genes share nearly 90% similarity, MORF4L2  is
unique to vertebrates whereas MRG15 is evolutionarily
conserved [14,37]. Similarly to MRG15, MORF4L2
directly interacts with MRFAP1 and the mSin3A co repres-
sor complex, components of which include HDAC1 and
HDCA2 and are involved in chromatin remodelling
[13,14]. MORF4L2 is reported to have both repressive and
stimulatory activity in transcription regulation of wellBMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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known cell cycle regulator, v-myb myeloblastosis viral
oncogene homolog (avian)-like 2 (MYBL2) [14,38].
MRFAP1 and MORFL2 were selected from Network B for
validation in 22 new samples as described above. In both
cases, six of seven CIN III samples showed the greatest
increase in expression (1.8 – 6.6 fold increase) and the
overall increasing trend was found to be statistically sig-
nificant (p value .033 and .017, respectively). We observed
a 2.0–2.5 fold increase in expression in cervical cancer
(T1). Together, these results validate the differential
expression again supporting a potential role of chromatin
remodelling in cervical cancer progression.
This differential expression in the chromatin remodelling
genes could result in changes in the organization of the
DNA. If these changes are large enough they could be
detectable. Previously, we quantified changes in nuclear
texture with increasing grade of CIN [39]. These measured
phenotype changes, as seen in Figure 7 (an updated graph
of the data), begin with CIN I and are more prominent in
the high grades of CIN (II, III) and cancer [39]. This
appears to correlate CIS with the novel observations pre-
sented in the present study with respect to the increased
expression of chromatin remodelling complex compo-
nents indicating that these expression changes result in an
alteration of the cell/nuclear phenotype.
Conclusion
Events in expression change involving genes in Network A
and Network B (DHFR, MORFL2, MRFAP1, NCOR1, and
SMARCC1) occur at or before the stage of moderate dys-
plasia (CIN II). These events are maintained, although at
a reduced frequency, in CIN III suggesting a role in inter-
mediate events prior to severe dysplasia that may be an
important stepping stone in disease progression.
Genomic instability is characteristic of CIN III lesions and
cervical cancer, as such the non-maintenance of such aber-
An updated box plot from Guillaud et al Figure 7
An updated box plot from Guillaud et al. showing the correlation between a linear discriminant function score (Texture 
Score) based entirely on only texture phenotype features measured of the nuclei in formalin fixed quantitatively stained sec-
tions of biopsied tissue [39]. The error bars represent the 5th and 95th percentiles; the box represents the central 50th percen-
tile and the solid square the mean of the distribution of the scores for measured sections with the noted histopathological 
diagnosis. The numbers over the boxes are the number of samples measured for the specific diagnosis.BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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rations in later stages may be due to the masking the of
initial events by additional changes acquired in severe
dysplasia [3,40,41].
Deregulation of chromatin remodelling functions has
analogous effects to mutation in DNA repair components
in that the repercussions can be genome wide. It is inter-
esting that evidentially two deregulated genes from both
networks investigated are associated with chromatin
remodelling (SMARCC1,  NCOR1,  MRFAP1,  MORF4L2)
and such disruptions are targeted to the critical stage of
moderate dysplasia. The increase in SWI/SNF stabilizing
molecule SMARCC1 and other novel genes has not been
previously illustrated as events in the early stages of dys-
plasia development thus providing not only novel candi-
date markers for screening but a biological function for
targeting treatment. Together, our results suggest altered
expression events in chromatin remodelling complex
components and influencing factors occur in precancer-
ous cervical intraepithelial neoplasia. Future investigation
on protein DNA interaction will be necessary to further
elucidate the precise role of chromatin remodelling in cer-
vical cancer progression.
Methods
Sample Selection and Collection
Specimens were collected as previously described [6],
immediately prior to the LEEP (Loop electrosurgical exci-
sion procedure) using bite biopsy targeting a small por-
tion of the affected epithelium. These specimens were
collected with patient consent and University of British
Columbia (UBC) British Columbia Cancer Agency
(BCCA) Research Ethics Board approval at the Vancouver
General Hospital Women's Clinic at the Vancouver Hos-
pital & Health Science Centre (VHHSC). Anonymized
cases were assessed by cervical cancer pathologists at
BCCA and were selected without prior knowledge of HPV
status. Specimens N1to N4 in this study were observed to
be non cancerous squamous epithelia whereas C1toC6
were identified as high grade dysplasia or CIN III. Speci-
mens M1to M3 were assessed as CIN I while M4to M6 as
CIN II. Detail description of LEEP cone specimens are
listed in Additional file 7. All samples were stored in a
RNA preservation solution (RNA later, Ambion) within 2
minutes of retrieval and then placed in storage at -80°C.
L-SAGE
The biopsies were homogenised in Lysis Binding buffer
(100 mM Tris-HCl, pH7.5, 500 mM LiCl, 10 mM EDTA,
pH 8.0, 1% LiDS, 5 mM dithiothreitol). Long SAGE librar-
ies were constructed using the L-SAGE kit (Invitrogen,
Ontario, Canada) and sequenced to an average depth of
155,000 tags allowing for deep sampling of the transcrip-
tome without an initial restriction to known genes [42-
44].
Analysis
Raw tag count data for each SAGE library was normalized
to tags per million (TPM) to facilitate comparison
between libraries. Each sequence tag was then mapped to
genes using the August 1 2006 version of SAGEGenie [45].
CIN I and CIN II libraries were grouped in analysis (CIN
I/CIN II or mild/moderate dysplasia). Subsequently,
those tags detected at a level of 20 TPM in at least one of
the NC libraries, CINI/CINII, and CINIII groups were
retained for differential expression analysis. To determine
differential expression between the three groups, a combi-
nation of a two-fold difference in means as well as a per-
mutation score ≥ 1.96 (corresponding to an unadjusted p-
value of 0.05) was used [46]. Briefly, the permutation test
used in this analysis examines the statistical significance
of the observed differences in means between two groups
in comparison to the average and standard deviation of
difference of 10,000 random permutations of the data.
cDNA synthesis
A validation panel of 12 cervical specimens (independent
from those used in the SAGE analysis) were assembled:
normal (Na, Nb, Nc), CIN I (CIa, CIb, CIc), CIN II (CIIa,
CIIb, CIIc) and CIN III (CIIIa, CIIIb, CIIIc). Specimens
were collected and stored as described above. RNA was
isolated as previously described [6]. In addition, cervix
squamous cell carcinoma (T1) and adjacent normal tissue
(N1) total RNA sample set was purchased (Ambion,
#7276). All cDNA was generated from 200 ng of total
RNA using the High Capacity TaqMan Reverse Transcrip-
tion Reagents (Applied Biosystems, Foster City, CA).
Realtime PCR Analysis
The expression levels of individual genes were analyzed by
real-time PCR using TaqMan® Gene Expression Assays in
triplicate in a new panel of 22 cases using the ABI 7500
Real-Time PCR System (Applied Biosystems). Taqman
probes (Assay IDs) include 18S  (Hs99999901_s1),
MORF4L2  (Hs0020211_m1),  MRFAP1
(Hs00738144_g1),  SMARCC1  (Hs00268265_m1),
NCOR1  (Hs00196920_m1),  DHFR  (Hs0075822_s1),
PTEN  (Hs00829813_s1), RBL2  (Hs00180562_m1) and
CDKN2B (Hs00793225_m1). The relative quantification
of the target genes in CIN I, CIN II and CIN III samples
compared to the average Ct of NC samples was performed
using the established 2-ΔΔCt method (Applied Biosystems,
Relative Quantitation Of Gene Expression, ABI PRISM
7700 Sequence Detection System: User Bulletin #2). Gene
expression is normalized to 18S. The relative quantifica-
tion values were then plotted, a ratio of one indicating no
change with respect to NC cervical tissue. A single squa-
mous cervical carcinoma sample and adjacent normal tis-
sue were also compared using this method (T1 and N1,
respectively).BMC Genomics 2008, 9:64 http://www.biomedcentral.com/1471-2164/9/64
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